Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rimonabant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Rimonabant. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001404-37 Sponsor Protocol Number: CARDIO-REDUSE Start Date*: 2006-09-12
    Sponsor Name:Maastricht University
    Full Title: Cardiometabolic risk reduction by Rimonabant: the effectiveness in daily practice and its use
    Medical condition: Despite therapeutic advances, cardio metabolic disease still remains an important cause of death worldwide. The endocannabinoid system seems to be a new target for multiple risk factor management a...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002492-14 Sponsor Protocol Number: EFC10139 Start Date*: 2008-03-28
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A randomized, double-blind, parallel-group, multicenter, multinational study to assess the long-term effect, over 1 year, of rimonabant 10 mg in comparison with rimonabant 20 mg after an initial tr...
    Medical condition: Patients with BMI > or = 30 kg/m2 or BMI > 27 kg/m2 with associated risk factors such as Type 2 Diabetes mellitus or Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    10.1 10045260 LLT
    10.1 10058108 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-003104-20 Sponsor Protocol Number: Rimona2011 Start Date*: 2011-10-06
    Sponsor Name:UZLeuven
    Full Title: The effect of Acomplia® (rimonabant) on esophageal sensitivity and gastric accommodation during food intake in healthy volunteers: a single-blind, placebo-controlled study
    Medical condition: study is conducted on healthy volunteers, no medical condition is investigated
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001787-71 Sponsor Protocol Number: CCB-CRC-07-01 Start Date*: 2008-02-11
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity
    Medical condition: Adiposity is another risk factor for developing cardiac insufficiency and myocardial hypertrophy. Probably the volume loading of the left ventricle, systemic inflammation, the fatty degeneration of...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001522-30 Sponsor Protocol Number: RIMOFATSCI-2 Start Date*: 2022-10-03
    Sponsor Name:Fundación Hospital Nacional de Parapléjicos
    Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries
    Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000819-16 Sponsor Protocol Number: VICSUB Start Date*: 2006-03-14
    Sponsor Name:HYKS, sisätautien toimiala, diabetesklinikka
    Full Title: RIMONABANT-LÄÄKEHOIDON JA LAIHDUTUKSEN VAIKUTUKSET MAKSAN RASVAPITOISUUTEEN JA RASVAKUDOKSEN AINEENVAIHDUNTAAN METABOLISTA OIREYHTYMÄÄ SAIRASTAVILLA POTILAILLA
    Medical condition: Tutkimukseen osallistuu korkeintaan 20 VICTORIA-tutkimukseen jo osallistuvaa keskivartalolihavaa metabolista oireyhtymää sairastavaa potilasta
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001613-17 Sponsor Protocol Number: CPR-EFC5593-EN-E01 Start Date*: 2006-02-27
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed- Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/day) on Glycemic Control in Type 2 Diabetic Pat...
    Medical condition: Type 2 Diabetic Patients Inadequately Controlled with Insulin
    Disease: Version SOC Term Classification Code Term Level
    8.0 10063624 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001716-71 Sponsor Protocol Number: RIMON_C_01346 Start Date*: 2006-09-12
    Sponsor Name:sanofi aventis Groupe
    Full Title: A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABO...
    Medical condition: PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC RISK FACTORS
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002568-27 Sponsor Protocol Number: PM-C-0172 Start Date*: 2006-05-08
    Sponsor Name:Sanofi-Synthelabo Groupe
    Full Title: A randomized, double blind, two-arm placebo controlled, 12-Month study of the effects of rimonabant 20mg once daily on the amount and the activity of visceral fat in abdominally obese patients with...
    Medical condition: Abdominally obese patients with metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029883 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DK (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-004497-40 Sponsor Protocol Number: METIGT2008 Start Date*: 2008-11-11
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo
    Medical condition: Impaired fasting glucose
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056997 Impaired fasting glucose LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001003-38 Sponsor Protocol Number: RGHT000540 Start Date*: 2008-08-01
    Sponsor Name:The Royal Group of Hospitals, Belfast Trust
    Full Title: A study investigating rimonabant versus placebo in conjunction with a strict low-fat weight reduction diet in overweight and obese subjects: effects on glucose and lipid metabolism and cardiovascul...
    Medical condition: This study will investigate subjects who are overweight and obese with Body Mass Index >27kg/m2.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002077-31 Sponsor Protocol Number: RIMON_L_01814 Start Date*: 2008-09-09
    Sponsor Name:SANOFI-AVENTIS S.P.A
    Full Title: Effects of Rimonabant on urinary albumin excretion rate on the components of the metabolic syndrome in patients with type 2 diabetes mellitus and microalbuminuria on background ramipril treatment. ...
    Medical condition: Abdominal obese patients with type 2 diabetes mellitus and microalbuminuria.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001711-30 Sponsor Protocol Number: RIMON_R_00961 Start Date*: 2006-10-11
    Sponsor Name:sanofi aventis Groupe
    Full Title: A Pan-European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with impaired fast...
    Medical condition: abdominally obese patients with impaired fasting blood glucose with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) CZ (Completed) SI (Completed) FR (Completed) NL (Prematurely Ended) NO (Completed) FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended) LT (Prematurely Ended) HU (Completed) SK (Completed) GR (Completed) AT (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000807-33 Sponsor Protocol Number: EFC5823 Start Date*: 2005-05-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized, double-blind, two -arms placebo-controlled, parallel-group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients.
    Medical condition: Abdominally obese patients with atherogenic dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058110 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003013-14 Sponsor Protocol Number: EFC10144 Start Date*: 2008-02-01
    Sponsor Name:sanofi-aventis recherche & development
    Full Title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH)
    Medical condition: Diabetic patients with Non-Alcoholic Steato-Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Suspended by CA) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006082-88 Sponsor Protocol Number: Rimonamaag Start Date*: 2008-10-21
    Sponsor Name:UZLeuven
    Full Title: INFLUENCE OF RIMONABANT ON GASTRIC SENSITIVITY AND ON THE GASTRIC RESPONSE TO A MEAL IN HEALTHY VOLUNTEERS
    Medical condition: none; this is a physiological study to investigate the influence of CB1 receptor antagonism by rimonabant (normally used for the treatment of obesity) on gastric sensorimotor function
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006424-18 Sponsor Protocol Number: EC/2006/117/PGMS Start Date*: 2007-03-01
    Sponsor Name:University of Surrey
    Full Title: THE EFFECT OF RIMONABANT ON ENERGY EXPENDITURE, FATTY ACID METABOLISM, TRIACYLGLYCEROL METABOLISM AND BODY FAT DISTRIBUTION
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    8.1 10029883 Obesity LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002500-26 Sponsor Protocol Number: EFC10231 Start Date*: 2008-10-13
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A multicenter, double blind, placebo controlled randomized study of the efficacy and safety of two rimonabant/metformin combinations for reducing A1C in the treatment of patients with type 2 diabet...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    11.0 10045242 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003012-61 Sponsor Protocol Number: EFC10143 Start Date*: 2008-02-01
    Sponsor Name:sanofi recherche & developpement
    Full Title: A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH)
    Medical condition: Non diabetic patients with Non-Alcoholic Steato-Hepatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053219 Non-alcoholic steatohepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Prematurely Ended) BE (Completed) ES (Completed) HU (Prematurely Ended) IT (Prematurely Ended) FR (Suspended by CA) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001715-30 Sponsor Protocol Number: RIMON_R_00962 Start Date*: 2006-10-23
    Sponsor Name:sanofi aventis Groupe
    Full Title: A European randomized, parallel group, two-arm placebo-controlled, double-blind multicenter study of Rimonabant 20mg once daily in the treatment of abdominally obese patients with dyslipidemia with...
    Medical condition: abdominally obese patients with dyslipidemia with or without other comorbidities
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) CZ (Completed) SI (Completed) NL (Completed) SE (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) SK (Completed) HU (Completed) GR (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 23:12:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA